14 results about "Metforminum" patented technology

Described herein is a rsew method for treating diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis with a growth hormone secretagogue alone or in combination with a drug selected from a dipeptidyl peptidase-4 antagonist a glucagon-like peptide receptor agonist, a thiazolidinedione, a sodium glucose transport protein 2 antagonist, arid metformin. Compositions relating to the same are also provided.

This invention discloses a composition for improving metabolic syndrome, its preparation method, and its application. The composition for improving metabolic syndrome comprises privet fruit, honeysuckle, wolfberry fruit, kudzu root, and astragalus root. The medicinal materials used in the formulation involved in this invention are all traditional Chinese medicinal herbs that are also used in food, exhibiting extremely high safety and definite efficacy. two and db In mice, it demonstrated clear efficacy in lowering blood sugar and improving metabolic syndrome, comparable to metformin, and even superior to metformin in some lipid parameters. Further mechanistic studies showed that the optimized formulation 3 can exert a synergistic effect by regulating multiple metabolic pathways, and can be used to regulate metabolic-related diseases such as diabetes, fatty liver, alcoholic liver disease, and dyslipidemia.

The present invention relates to a composition of an immunomodulatory therapeutic agent by inducing transplantation of a mitochondrial derived from an induced pluripotent stem cell (iPSC), and it is confirmed that the mitochondrial derived from the iPSC according to the present invention overexpresses UCP2, and the expression of the UCP2 is related to an immunomodulatory effect, and more particularly, to a composition of an immunomodulatory therapeutic agent by inducing transplantation of the mitochondrial derived from the iPSC. In addition, it has been confirmed that mitochondrial function is enhanced after administration of an iPSC-derived mitochondrial, thereby increasing ATP synthesis and mitochondrial membrane potential. Moreover, it has been confirmed that the expression of immune cells associated with autoimmune diseases is regulated, and when used in combination with metformin, it has been confirmed that a synergistic effect on the regulation effect of immune cells has been confirmed. In addition, it was confirmed that the disease activity of autoimmune diseases is reduced, and the expression of autoimmune-related cells is suppressed. Moreover, it has been confirmed that, when a peripheral blood mononuclear cell is treated with an iPSC-derived mitochondrion, the expression of Th17 is suppressed and the expression of Treg is increased, thereby improving the immune regulation and disease activity of various immune diseases.

A combination of medications and medication doses is disclosed whereby age-related changes in systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color, thymotrophic hormones, immune cell populations, the CD4 / CD8 cell ratio, bone marrow density, thymus structure, kidney function, and epigenetic age can be reversed in humans. Surprisingly, agents that accelerate the growth of cells reduce cancer risk, agents that intensify immune responses attenuate age-related inflammation, agents with no prior connection to hair color reverse age-related hair whitening, and a combination of agents that induces IGF-1, a hormone previously thought to drive systemic aging, results in a reversal of systemic aging as documented by an epigenetic clock. Medication combinations useful in the present invention include human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin.

The present disclosure provides the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in treating a neurological disease associated with repeat expansions and / or RAN protein accumulation, reducing the level of one or more repeat associated non-ATG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and / or biological sample. Also provided is the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in inhibiting RAN protein translation in a subject and in a biological sample (e.g., cells, tissue). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) for treating diseases associated with repeat expansions. Exemplary diseases associated with repeat expansions include, but are not limited to, C9ORFf72 amyotrophic lateral sclerosis (ALS), or C9ORFf72 frontotemporal dementia; myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2); spinocerebellar ataxia; Huntington's disease; Fragile X Tremor Ataxia Syndrome (FXTAS); and Fragile XE syndrome (FRAXE).

The present invention describes novel solid phases comprising metformin (MET) and a molecule having a hydroxyl, carboxyl or phenol group as co-formers, with improved pharmaceutical properties in comparison with metformin compounds already known in the prior art. In some embodiments of the present invention, the co-forming agents are selected from anticholesterolemic agents, antilipidemic agents and antioxidants. Preferably, the solid phases can be included in pharmaceutical compositions. Other embodiments of the invention describe the uses of the solid phases to manufacture a drug for treating or preventing metabolic syndrome and / or diabetes.

The invention belongs to the technical field of biomedical treatment, and particularly relates to an application of Roseburia inulinivorans. The invention provides an application of Roseburia inulinivorans in the preparation of a medicine for treating and / or preventing diabetes mellitus, and a preparation method of the Roseburia inulinivorans. The intestinal bacteria Roseburia inulinivorans can relieve type 2 diabetes mellitus by adjusting intestinal microorganisms and metabolites thereof, protecting the integrity of intestinal barriers and improving the inflammatory state and insulin resistance, particularly, the curative effect of the intestinal bacteria Roseburia inulinivorans is close to the therapeutic effect of a clinical conventional medicine metformin, and the intestinal bacteria Roseburia inulinivorans are small in side effect, more stable in therapeutic effect, small in economic burden and more suitable for application and popularization.

The invention provides application of hermetia illucens total protein in preparation of products for preventing and / or treating type 2 diabetes mellitus, and belongs to the technical field of biological medicine. The invention provides application of hermetia illucens total protein in any one of the following items: (1) preparing a product for preventing and / or treating type 2 diabetes mellitus; and (2) preparing the product for regulating the intestinal flora of the individual type 2 diabetes mellitus. The invention further provides application of the combination of the hermetia illucens total protein and metformin in preparation of a product for treating type 2 diabetes mellitus. The application of the hermetia illucens total protein to the prevention and treatment of the type 2 diabetes mellitus is proposed for the first time, academic innovation is achieved, and a new thought is provided for research and development of a low-cost and high-safety method for intervening the type 2 diabetes mellitus with natural components. Based on efficacy evaluation and action mechanism mining of the hermetia illucens total protein, the total protein extract is used for resisting type 2 diabetes, the application range of hermetia illucens resources is expanded, and a new direction is provided for intervention of type 2 diabetes.

The invention provides an improvement effect of metformin on post-traumatic stress disorder, and belongs to the technical field of biological medicine. Metformin is used for relieving unbalance of mitochondrial homeostasis in amygdala nucleus on the outer side of a post-traumatic stress disorder model rat by promoting mitochondrial biosynthesis, so that synaptic and dendritic spine abnormity is improved, finally fear memory regression of the post-traumatic stress disorder model rat is promoted, and the post-traumatic stress disorder is improved.

The invention relates to the technical fields of biological material technologies, medicinal chemistry and medicinal preparations, in particular to a double-stimulation response type sodium alginate grafted metformin / chitosan nanoparticle as well as a preparation method and application thereof. Comprising the following steps: (1) synthesizing sodium alginate grafted metformin: preparing sodium alginate grafted metformin through an amidation condensation reaction catalyzed by EDC / NHS; and (2) preparing the sodium alginate grafted metformin / chitosan nanoparticles: carrying out polyelectrolyte complexation reaction to obtain the nanoparticles. The synthesis method is simple in path, and the prepared nanoparticles are good in dispersity, uniform in particle size and good in stability and have the pH and intestinal flora double-stimulation response characteristic. The metformin oral delivery system can overcome the gastric acid barrier and prolong the residence time of metformin in an intestinal flora enrichment area during oral delivery, greatly improves the intestinal delivery efficiency, can be applied to metformin oral targeting delivery of various metabolic diseases including type 2 diabetes and metabolic syndrome, and enhances the treatment effect of metformin.

According to the fluorescent probe disclosed by the invention, the response to the pH is realized through intramolecular cyclization and ring opening mechanisms, and the response to the pH is reversible. Under the condition of pH triggering, the fluorescent probe LD-Nu-APP can dye the lipid droplets and the nucleolus and emit green fluorescence and red fluorescence respectively. The advantages of two-parameter detection (lipid content and nucleolus size) of the fluorescent probe LD-Nu-APP are utilized, the non-alcoholic fatty liver tissue and the normal tissue can be successfully distinguished, and the method is more accurate than Nile red which only depends on lipid change. Besides, based on the Bayesian theorem, the fluorescent probe LD-Nu-APP is used for screening and evaluating the two drugs for treating the non-alcoholic fatty liver disease, and it is found that pioglitazone is more effective than metformin, and the application range is wider. In conclusion, it is believed that the fluorescent probe LD-Nu-APP has unique lipid content-nucleolus size two-parameter detection characteristics and has huge value in non-alcoholic fatty liver disease diagnosis and drug screening.

This application discloses a terbium-doped benzenepolycarboxylic acid-bismethylguanidine (HOF) material and its application in the detection of the explosive precursor sodium hypochlorite, belonging to the field of fluorescent probes and fluorescent detection technology. This terbium-doped benzenepolycarboxylic acid-bismethylguanidine (HOF) material consists of an HOF matrix and rare earth metal ions (Tb). 3+ The HOF matrix is ​​composed of a coordination complex and is constructed from a benzene polycarboxylic acid compound and metformin hydrochloride through intermolecular hydrogen bonding self-assembly. This material can pass through Tb... 3+ Characteristic fluorescence emission at 545nm ( 5 D4→ 7 The F5 transition exhibits a highly selective fluorescence quenching response to sodium hypochlorite (NaClO), with a low detection limit and a wide linear range, enabling rapid and highly sensitive detection of low concentrations of NaClO. This is of great significance for blocking NaClO-based explosive synthesis.

The application relates to the technical field of pharmaceutical preparation, and provides a metformin hydrochloride gastric floating sustained-release microtablet. The component composition of the metformin hydrochloride gastric floating sustained-release microtablet comprises, in percentage by weight, 50%-75% of metformin hydrochloride, 5%-20% of a skeleton material, 9%-18% of a filling agent, 2%-6% of a floating aid, 1%-4% of a lubricant and 1%-3% of a nano modifier. The metformin hydrochloride gastric floating sustained-release microtablet can prolong the residence time of metformin hydrochloride in the stomach and the upper part of the small intestine, and improve the drug utilization.

The invention discloses an application of morchella polysaccharide nano-selenium in preparation of a preparation for improving insulin resistance. The morchella polysaccharide nano-selenium is MSP4-SeNPs, the particle size of the morchella polysaccharide nano-selenium is 67.45 + / -0.52 nm, and the selenium content of the morchella polysaccharide nano-selenium is 52.6 + / -3.21 mg / kg; cell experiments prove that the improvement effect of the MSP4-SeNPs with the concentration of 6.25 mu g / mL on cell insulin resistance is equivalent to the improvement effect of a metformin solution with the concentration of 100 mu g / mL, and the MSP4-SeNPs can be applied to preparation of a preparation for improving insulin resistance. Animal experiments prove that the MSP4-SeNPs with the concentration of 4 mg / kg has the treatment effect on glucose metabolism disorder syndrome or metabolic syndrome caused by insulin resistance equivalent to that of a metformin solution with the concentration of 100 mg / kg, can be particularly used for treating type II diabetes mellitus, and has the advantages of low dosage and no side effect compared with the existing medicine metformin.